SV2017005487A - Derivados de 4h-pirrol[3,2-c]piridin-4-ona - Google Patents
Derivados de 4h-pirrol[3,2-c]piridin-4-onaInfo
- Publication number
- SV2017005487A SV2017005487A SV2017005487A SV2017005487A SV2017005487A SV 2017005487 A SV2017005487 A SV 2017005487A SV 2017005487 A SV2017005487 A SV 2017005487A SV 2017005487 A SV2017005487 A SV 2017005487A SV 2017005487 A SV2017005487 A SV 2017005487A
- Authority
- SV
- El Salvador
- Prior art keywords
- pirrol
- piridin
- ona
- derivatives
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPUESTOS DE FÓRMULA (I): (VER FORMULA); PROCESOS PARA SU PRODUCCIÓN Y SU USO COMO FÁRMACOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15152944 | 2015-01-28 | ||
| EP15200407 | 2015-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005487A true SV2017005487A (es) | 2019-01-17 |
Family
ID=55236350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005487A SV2017005487A (es) | 2015-01-28 | 2017-07-28 | Derivados de 4h-pirrol[3,2-c]piridin-4-ona |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10428063B2 (es) |
| EP (1) | EP3250567B1 (es) |
| JP (1) | JP6704398B2 (es) |
| KR (1) | KR102544847B1 (es) |
| CN (1) | CN107406417B (es) |
| AU (1) | AU2016212230B2 (es) |
| BR (1) | BR112017016193B1 (es) |
| CA (1) | CA2974853C (es) |
| CL (1) | CL2017001930A1 (es) |
| CO (1) | CO2017007663A2 (es) |
| CR (1) | CR20170345A (es) |
| CU (1) | CU20170094A7 (es) |
| DO (1) | DOP2017000176A (es) |
| EA (1) | EA032530B1 (es) |
| EC (1) | ECSP17048527A (es) |
| IL (1) | IL253284B (es) |
| JO (1) | JO3706B1 (es) |
| MX (1) | MX380239B (es) |
| MY (1) | MY182181A (es) |
| NI (1) | NI201700096A (es) |
| PE (1) | PE20171240A1 (es) |
| PH (1) | PH12017501340A1 (es) |
| SG (1) | SG11201705908VA (es) |
| SV (1) | SV2017005487A (es) |
| TN (1) | TN2017000329A1 (es) |
| TW (1) | TWI699359B (es) |
| UA (1) | UA122221C2 (es) |
| UY (1) | UY36544A (es) |
| WO (1) | WO2016120196A1 (es) |
| ZA (1) | ZA201705802B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015193339A1 (en) | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| EP3331611B1 (en) | 2015-08-05 | 2021-06-02 | Bayer Pharma Aktiengesellschaft | 1h-pyrrol-3-amines |
| EP3782994B1 (en) | 2015-12-16 | 2025-07-16 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| KR102440006B1 (ko) | 2017-08-23 | 2022-09-05 | 현대모비스 주식회사 | 차량용 브레이크의 캘리퍼 장치 |
| US11339157B1 (en) | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| US12240844B2 (en) | 2019-01-18 | 2025-03-04 | Voronoi, Inc. | Pyrrolopyridine derivative and use thereof in prevention and treatment of protein kinase-related disease |
| WO2020161257A1 (en) | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
| WO2020216774A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| WO2020216773A1 (en) | 2019-04-24 | 2020-10-29 | Bayer Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one compounds |
| BR112021019998B1 (pt) * | 2019-04-24 | 2024-01-16 | The Broad Institute, Inc. | 4h-pirrolo[3,2-c]piridin-4-ona, seus usos, composição farmacêutica, e kit de partes |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| EP4188930B1 (en) | 2020-07-29 | 2024-10-23 | Bayer Aktiengesellschaft | Substituted heterocyclic compounds and therapeutic uses thereof |
| WO2022023339A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| WO2022023337A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof |
| WO2022023341A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof |
| CN115836070B (zh) * | 2020-08-10 | 2024-08-09 | 上海和誉生物医药科技有限公司 | 作为egfr抑制剂的稠环化合物及其制备方法和应用 |
| EP4217070A1 (en) * | 2020-09-23 | 2023-08-02 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| CN116997549A (zh) * | 2020-09-23 | 2023-11-03 | 蝎子疗法股份有限公司 | 用于治疗癌症的吡咯并[3,2-c]吡啶-4-酮衍生物 |
| WO2022072645A2 (en) * | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| JP2023548657A (ja) * | 2020-10-09 | 2023-11-20 | スコーピオン セラピューティクス インコーポレイテッド | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 |
| CN116981667A (zh) * | 2020-10-09 | 2023-10-31 | 蝎子疗法股份有限公司 | 用于癌症治疗的egfr和/或her2的杂环抑制剂 |
| WO2022094271A1 (en) * | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) * | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2023147015A1 (en) * | 2022-01-27 | 2023-08-03 | The Broad Institute, Inc. | Substituted heterocyclic csnk1 inhibitors |
| CA3246654A1 (en) | 2022-03-24 | 2023-09-28 | Scorpion Therapeutics Inc | METHODS FOR SYNTHESIZING EGFR INHIBITORS |
| WO2024182715A1 (en) * | 2023-03-02 | 2024-09-06 | Schrödinger, Inc. | Heterocyclics as egfr inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
| US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
| WO2009040399A1 (en) | 2007-09-28 | 2009-04-02 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| US8916591B2 (en) | 2008-01-22 | 2014-12-23 | Vernalis (R&D) Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| ES2679379T3 (es) | 2009-06-15 | 2018-08-24 | Nerviano Medical Sciences S.R.L. | Derivados de pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| EP2788350B1 (en) * | 2011-10-07 | 2017-12-06 | Nerviano Medical Sciences S.r.l. | 4-ALKYL SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-a]PYRAZIN-1(2H)-ONE DERIVATIVES AS KINASES INHIBITORS |
| CN103906732A (zh) | 2011-10-28 | 2014-07-02 | 株式会社钟根堂 | 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物 |
| JP6141866B2 (ja) | 2011-12-21 | 2017-06-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンジルピラゾール類 |
| HK1207861A1 (en) | 2012-05-11 | 2016-02-12 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| WO2014022752A1 (en) | 2012-08-03 | 2014-02-06 | Amgen Inc. | Macrocycles as pim inhibitors |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| WO2014147204A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP3010901B1 (en) | 2013-06-21 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3010902A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| EP3010911A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2015022073A1 (en) | 2013-08-13 | 2015-02-19 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
| WO2015193339A1 (en) * | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| EP3331611B1 (en) | 2015-08-05 | 2021-06-02 | Bayer Pharma Aktiengesellschaft | 1h-pyrrol-3-amines |
| CA3008393A1 (en) | 2015-12-16 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
-
2016
- 2016-01-25 CN CN201680013096.2A patent/CN107406417B/zh active Active
- 2016-01-25 PE PE2017001288A patent/PE20171240A1/es unknown
- 2016-01-25 WO PCT/EP2016/051432 patent/WO2016120196A1/en not_active Ceased
- 2016-01-25 AU AU2016212230A patent/AU2016212230B2/en active Active
- 2016-01-25 BR BR112017016193-1A patent/BR112017016193B1/pt active IP Right Grant
- 2016-01-25 US US15/547,032 patent/US10428063B2/en active Active
- 2016-01-25 JP JP2017539454A patent/JP6704398B2/ja active Active
- 2016-01-25 TN TNP/2017/000329A patent/TN2017000329A1/en unknown
- 2016-01-25 MY MYPI2017702724A patent/MY182181A/en unknown
- 2016-01-25 CU CUP2017000094A patent/CU20170094A7/es unknown
- 2016-01-25 MX MX2017009831A patent/MX380239B/es unknown
- 2016-01-25 SG SG11201705908VA patent/SG11201705908VA/en unknown
- 2016-01-25 EP EP16701600.5A patent/EP3250567B1/en active Active
- 2016-01-25 EA EA201791692A patent/EA032530B1/ru not_active IP Right Cessation
- 2016-01-25 CR CR20170345A patent/CR20170345A/es unknown
- 2016-01-25 UA UAA201708621A patent/UA122221C2/uk unknown
- 2016-01-25 KR KR1020177023372A patent/KR102544847B1/ko active Active
- 2016-01-25 CA CA2974853A patent/CA2974853C/en active Active
- 2016-01-27 JO JOP/2016/0014A patent/JO3706B1/ar active
- 2016-01-28 UY UY0001036544A patent/UY36544A/es not_active Application Discontinuation
- 2016-01-28 TW TW105102745A patent/TWI699359B/zh active
-
2017
- 2017-07-03 IL IL253284A patent/IL253284B/en active IP Right Grant
- 2017-07-25 PH PH12017501340A patent/PH12017501340A1/en unknown
- 2017-07-27 EC ECIEPI201748527A patent/ECSP17048527A/es unknown
- 2017-07-28 DO DO2017000176A patent/DOP2017000176A/es unknown
- 2017-07-28 CO CONC2017/0007663A patent/CO2017007663A2/es unknown
- 2017-07-28 SV SV2017005487A patent/SV2017005487A/es unknown
- 2017-07-28 NI NI201700096A patent/NI201700096A/es unknown
- 2017-07-28 CL CL2017001930A patent/CL2017001930A1/es unknown
- 2017-08-25 ZA ZA2017/05802A patent/ZA201705802B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005487A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| UY35467A (es) | Compuestos orgánicos | |
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
| CO7210068A1 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2014000062A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| GT201500138A (es) | Novedososo derivados de bencimidazol como antagonistas de ep4 | |
| MX2017004200A (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
| CR20150470A (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| UY35499A (es) | Indazoles sustituidos con diaminoheteroarilo | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| SV2018005657A (es) | "nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparacion y composiciones farmaceuticas que los contienen" | |
| UY34273A (es) | Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación | |
| UY35610A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| UY35665A (es) | ?compuestos de carboxamida, proceso de preparación y su uso como nematicidas?. | |
| MX373441B (es) | Derivados de indol-urea glucopiranosil-sustituido y su uso como inhibidores sglt. |